Specializing In:
- Acute myeloid leukemia
- Myelodysplastic syndromes
- Chronic Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Blastic plasmacytoid dendritic cell neoplasm
- Myeloproliferative neoplasms
Research Interests:
- Acute myeloid leukemia
- Molecular and genomic biomarkers in myeloid malignancies
- Targeted therapies and novel therapeutics
- Clonal hematopoiesis
- Myelodysplastic syndromes
- Blastic plasmacytoid dendritic cell neoplasm
- Chimeric antigen receptor (CAR) T cell therapy
Biography
I am a physician and hematology-oncology fellow at Roswell Park Comprehensive Cancer Center with a clinical and research interest in hematologic malignancies, particularly acute myeloid leukemia and other myeloid neoplasms.
Before joining Roswell Park, I completed a dedicated leukemia fellowship at The University of Texas MD Anderson Cancer Center, where I trained in the care of patients with acute and chronic leukemias and gained experience with novel targeted therapies, clinical trials, and cellular therapies. During my fellowship, I also served as Secretary of the GME House Staff Senate.
My research focuses on understanding how the molecular and genomic characteristics of leukemia influence treatment response and outcomes, with a particular interest in acute myeloid leukemia, clonal hematopoiesis, and the development of novel and targeted therapies. My goal is to integrate clinical care and research to improve treatment options and outcomes for patients with hematologic malignancies.
Positions
Roswell Park Comprehensive Cancer Center
- Fellow - Hematology and Medical Oncology (Class of 2029)
- Department of Medicine
Background
Education and Training
- MBBS – Adesh Institute of Medical Sciences & Research, India
Residency
- 2022-2026 – Internal Medicine Residency - UCHealth Parkview Medical Center, Pueblo, Colorado
Fellowship
- 2025–2026 – Leukemia Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas
- 2021-2022 – Hematology Research Fellowship Mayo Clinic, Rochester, Minnesota
Board Certification
- Internal Medicine - American Board of Internal Medicine
Professional Memberships
- American Society of Hematology
- American Society of Clinical Oncology
Professional Experience
- Secretary, GME House Senate (2025–2026): The University of Texas MD Anderson Cancer Center, Houston, Texas
- Research Chief Resident (2023–2025): UCHealth Parkview Medical Center, Pueblo, Colorado
Honors & Awards
- Abstract Achievement Award, American Society of Hematology, 2025
- National Poster Winner, American College of Physicians, 2024
Publications
- Singh A, Daver N, Loghavi S, Kadia T, Ravandi F, DiNardo C, Borthakur G, Pierce S, Futreal A, Aung PP, Cuglievan B, Jain N, Jabbour E, Garcia-Manero G, Konopleva M, Qazilbash M, Pemmaraju N. Ten-year long-term survivors of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Leuk Lymphoma. 2026 Feb 19:1-4. doi: 10.1080/10428194.2026.2631115.
- Singh A, et al. Outcomes for adults with KMT2A-r acute myeloid leukemia treated with venetoclax plus azacitidine (Ven/Aza) or intensive chemotherapy (IC): A single-center retrospective study. ASCO 2025. DOI: 10.1200/JCO.2025.43.16_suppl.e18537
- Singh A, et al. Clinical outcomes of patients with IDH1/IDH2-mutated clonal hematopoiesis: A single-center retrospective study. Blood 2025. https://doi.org/10.1182/blood-2025-6710.
- Singh A, et al. Impact of NPM1 co-mutation on outcomes in RAS-mutated Acute Myeloid Leukemia. Blood 2025. https://doi.org/10.1182/blood-2025-7029.
- Singh A, et al. Optimizing the treatment of secondary central nervous system lymphoma (SCNSL) with intensive systemic and CNS-targeted chemoimmunotherapy followed by autologous stem cell transplant (ASCT): A retrospective, single-center analysis of a modified Ferreri protocol. Blood 2025. https://doi.org/10.1182/blood-2025-2727
- Singh A, Al-Kali A, Begna KH, et al. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases. Am J Hematol. 2022;97(5):630-637. doi: 10.1002/ajh.26498.
- Singh A, Al-Kali A, Foran JM, et al. Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting. Am J Hematol. 2022;97(10):E377-E379. doi: 10.1002/ajh.26672